GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
Clinical Evaluation of GW815SF for Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema) A Long-term Treatment Study of GW815SF50/500µg in Chronic Obstructive Pulmonary Disease -
Sponsor: GlaxoSmithKline
Listed as NCT00269087, this PHASE3 trial focuses on Pulmonary Disease, Chronic Obstructive and remains completed. Sponsored by GlaxoSmithKline, it has been updated 8 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Mar 2019 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Apr 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Apr 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jan 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .